Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Atrium Therapeutics dosed the first patient in Corventis, a global Phase 1/2 trial of ATR 1072, its lead siRNA antibody-oligonucleotide conjugate targeting PRKAG2 syndrome. The trial will enroll approximately 37 participants, with Part A ascending-dose cohorts for safety and a Part B single-arm expansion at the recommended Phase 2 dose; initial proof-of-concept data are expected in the second half of 2027.
Key figures
- Drug Name
- ATR 1072
- Phase Of Trial
- Phase 1/2
- Planned enrollment
- approximately 37 participants
- Us prevalence prkag2
- 1,000 - 2,000 people
- Proof of concept data timing
- second half of 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.